Published on 17/08/2022 12:55:09 PM | Source: ICICI Direct
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel https://t.me/InvestmentGuruIndia
Download Telegram App before Joining the Channel
Weak poultry performance continues to weigh on numbers
About the stock: Abbott India is one of the fastest growing listed MNC pharma companies. It has outperformed the industry on a consistent basis in women’s health, GI, metabolic, pain, CNS among othe
* The company’s top five brands - (Mixtard, Thyronorm, Novomix, Udiliv and Duphaston) together posted revenue CAGR of ~6.6% MAT, March 2019-22
* Abbott has 140+ brands in segments of women’s health, gastroenterology, metabolics, CNS, multi-specialty, vaccines & consumer healthQ1FY23 Results: Numbers weak as poultry farm economics turned adverse.
Q1FY23 Results: Abbott India’s revenues were in line with our expectations while margins were marginally lower
* Sales were up 7% YoY to | 1304 crore
* EBITDA was at | 270 crore, up 2% YoY with margins at 20.7%
* Consequent PAT was at | 206 crore (up 5% YoY
What should investors do? Abbott’s share price has grown by ~2.2x over the past three years (from ~| 8434 in August 2019 to ~| 18762 levels in Aug 2022)
* Downgrade from BUY to HOLD as valuations at current level largely factor power brands growth momentum and growing traction for new brands
Target Price and Valuation: Valued at | 21140 i.e. 40x FY24E EPS of | 528.6
Key triggers for future price performance:
* Consistency in brand-driven growth driven by favourable market dynamics with doctor prescription stickiness and lower perceived risk factors
* NLEM price hike of ~10.8% for estimated NLEM portfolio exposure of ~21% for Abbott may have positive impact on price led growth
* Focus on new launches, which is fairly consistent (+100 launches and line extensions in the last 10 years)
* Future launches from key divisions, along with brand extensions and access to innovative molecules from global parent to drive growth
Alternate Stock Idea: Apart from Abbott, in our healthcare coverage we like Pfizer.
* Pfizer is following a measured approach with de-focusing and hiving off of tail brands and focusing on core strengths areas such as vaccines, pain management, VMS, GI and CVS
To Read Complete Report & Disclaimer Click Here
For More ICICI Securities Disclaimer https://www.icicisecurities.com/AboutUs.aspx About=7
Above views are of the author and not of the website kindly read disclaimer
